NR AKRP
AU Seman,M.; Adjou,K.T.
TI [Therapeutic prospects for subacute transmissible spongiform encephalopathies]
OT Perspectives therapeutiques des encephalopathies subaigues spongiformes transmissibles
QU Revue du Praticien 1999 May 1; 49(9): 971-5
PT journal article; review; review, tutorial
AB There is currently no effective therapy available for Creutzfeldt-Jakob disease. However, a limited number of drugs such as polyanions, the amyloid-binding dye Congo red, amphotericin B and anthracyclines have been found to delay the appearance of the clinical signs in experimental prion diseases. Today, the most promising agent appears to be less toxic derivative the amphotericin B, MS-8209. Indeed this compound has a wide spectrum of anti-prion activity and constitute the unique molecule able to prolong survival time when treatment is performed at the late stages of infection. This result represents an important progress in therapeutical approaches of prion diseases and justify the development of new polyene antibiotic derivatives.
ZR 24
MH Amphotericin B/*analogs & derivatives/*therapeutic use; Antibiotics, Anthracycline/therapeutic use; Antibiotics, Macrolide/therapeutic use; Antiviral Agents/*therapeutic use; Creutzfeldt-Jakob Syndrome/*drug therapy/pathology; Disease Progression; English Abstract; Human; Polymers/therapeutic use; Prognosis
AD Laboratoire d'immunodifferenciation Institut Jacques-Monod Universite Paris VII 2, place jussieu 75005 Paris.
SP französisch
PO Frankreich